Confirmed efficacy and safety of dual therapy based in lamivudine plus a ritonavir-boosted protease inhibitor in the clinical setting

被引：0
|
作者：
Fontecha-Ortega, Maria [1 ]
Munoz-Mendoza, Vanessa [2 ]
Gomez, Cristina [3 ]
Sanchez-Conde, Matilde [3 ]
Angel Rodriguez, Miguel [3 ]
Jesus Vivancos, Maria [3 ]
Luis Casado, Jose [3 ]
机构：
[1] Hosp Getafe, Internal Med, Getafe, Spain
[2] Hosp Obispo Polanco, Internal Med, Teruel, Spain
[3] Hosp Ramon & Cajal, Infect Dis, Madrid, Spain
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P103
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Atazanavir and lopinavir/ritonavir:: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Ribera, E
    Azuaje, C
    Lopez, RM
    Diaz, M
    Feijoo, M
    Pou, L
    Crespo, M
    Curran, A
    Ocaña, I
    Pahissa, A
    AIDS, 2006, 20 (08) : 1131 - 1139
  • [32] Tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI) regimens appear to be associated with greater renal function decline
    Reactions Weekly, 2008, 1188 (1) : 4 - 4
  • [33] Dual therapy with dolutegravir plus ritonavir-boosted or unboosted atazanavir as a maintenance treatment in highly experienced HIV-infected patients
    Faycal, A.
    Abdi, B.
    Peytavin, G.
    Tebano, G.
    Schneider, L.
    Seang, S.
    Simon, A.
    Tubiana, R.
    Valantin, M.
    Marcelin, A.
    Katlama, C.
    Palich, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [34] Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy
    Orrell, Catherine
    Kaplan, Richard
    LANCET INFECTIOUS DISEASES, 2015, 15 (07): : 748 - 749
  • [35] Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen
    Cameron, D. William
    Becker, Stephen
    King, Martin S.
    da Silva, Barbara
    Klein, Cheri
    Tokimoto, Debbie
    Foit, Cheryl
    Calhoun, Deborah
    Bernstein, Barry
    Hanna, George J.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (05) : 957 - 963
  • [36] Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
    Cao, Ying
    Han, Yang
    Xie, Jing
    Cui, Qu
    Zhang, Lixia
    Li, Yijia
    Li, Yanling
    Song, Xiaojing
    Zhu, Ting
    Li, Taisheng
    BMC INFECTIOUS DISEASES, 2013, 13
  • [37] Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
    Ying Cao
    Yang Han
    Jing Xie
    Qu Cui
    Lixia Zhang
    Yijia Li
    Yanling Li
    Xiaojing Song
    Ting Zhu
    Taisheng Li
    BMC Infectious Diseases, 13
  • [38] Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study
    Calza, Leonardo
    Magistrelli, Eleonora
    Colangeli, Vincenzo
    Borderi, Marco
    Conti, Matteo
    Mancini, Rita
    Viale, Pierluigi
    ANTIVIRAL THERAPY, 2016, 21 (03) : 217 - 224
  • [39] Switching from a second-line ritonavir-boosted protease inhibitor-based regimen to bictegravir/emtricitabine/ tenofovir alafenamide: results of a randomized clinical trial
    Pierre, S.
    Marc, J. B.
    Homeus, F.
    Bernadin, G. R.
    Trevisi, L.
    Jean, E.
    Dumont, E.
    Sundaresan, S.
    Rivera, V.
    Israelski, D.
    Collins, S. E.
    Pape, J. W.
    Liautaud, B.
    Severe, P.
    Sax, P. E.
    Koenig, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 26 - 26
  • [40] Effect of Ritonavir-Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy
    Moreira, Sebastian A.
    Morcos, Peter N.
    Navarro, Mercidita T.
    Bech, Nuria
    Smith, Patrick F.
    Brennan, Barbara J.
    PHARMACOTHERAPY, 2014, 34 (03): : 220 - 226
12345